Investigational Drug Information for Gossypol
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the drug development status for Gossypol?
Gossypol is an investigational drug.
There have been 10 clinical trials for Gossypol.
The most recent clinical trial was a Phase 2 trial, which was initiated on September 1st 2013.
The most common disease conditions in clinical trials are Lung Neoplasms, Glioblastoma, and Small Cell Lung Carcinoma. The leading clinical trial sponsors are National Cancer Institute (NCI), Mayo Clinic, and Sidney Kimmel Comprehensive Cancer Center.
There is one US patent protecting this investigational drug and eight international patents.
Summary for Gossypol
| US Patents | 1,088 |
| International Patents | 8,601 |
| US Patent Applications | 3,600 |
| WIPO Patent Applications | 1,505 |
| Japanese Patent Applications | 1,320 |
| Clinical Trial Progress | Phase 2 (2013-09-01) |
| Vendors | 102 |
Recent Clinical Trials for Gossypol
| Title | Sponsor | Phase |
|---|---|---|
| R-(-)-Gossypol Acetic Acid With Lenalidomide and Dexamethasone in Treating Patients With Relapsed Symptomatic Multiple Myeloma | National Cancer Institute (NCI) | Phase 1 |
| R-(-)-Gossypol Acetic Acid With Lenalidomide and Dexamethasone in Treating Patients With Relapsed Symptomatic Multiple Myeloma | Mayo Clinic | Phase 1 |
| Lenalidomide and AT-101 in Treating Patients With Relapsed B-Cell Chronic Lymphocytic Leukemia | National Cancer Institute (NCI) | Phase 1/Phase 2 |
Clinical Trial Summary for Gossypol
Top disease conditions for Gossypol
Top clinical trial sponsors for Gossypol
US Patents for Gossypol
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Gossypol | See Plans and Pricing | Heterocyclic compounds useful in the treatment of disease | Epigen Biosciences, Inc. (San Diego, CA) | See Plans and Pricing |
| Gossypol | See Plans and Pricing | Pyrazol-3-ones that activate pro-apoptotic BAX | Dana-Farber Cancer Institute, Inc. (Boston, MA) | See Plans and Pricing |
| Gossypol | See Plans and Pricing | Small molecules for the modulation of MCL-1 and methods of modulating cell death, cell division, cell differentiation and methods of treating disorders | Dana-Farber Cancer Institute, Inc. (Boston, MA) | See Plans and Pricing |
| Gossypol | See Plans and Pricing | Methods for sensitizing a quiescent cancer stem cell to a BCR-ABL inhibitor | The Regents of the University of California (Oakland, CA) | See Plans and Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Gossypol
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Gossypol | Australia | AU2014232383 | 2033-03-15 | See Plans and Pricing |
| Gossypol | Australia | AU2019202731 | 2033-03-15 | See Plans and Pricing |
| Gossypol | Australia | AU2019288275 | 2033-03-15 | See Plans and Pricing |
| Gossypol | Brazil | BR112015023267 | 2033-03-15 | See Plans and Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
